OptiNose Inc. (OPTN)
Industry: Drug Manufacturers – Specialty & Generic
Sector: Healthcare
OptiNose, Inc. is a specialty pharmaceutical company that develops and commercializes products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company's flagship product, XHANCE, is a therapeutic product that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE utilizes OptiNose's proprietary exhalation delivery system (EDS). The company also offers Onzetra Xsail, a powder EDS device. OptiNose has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
Financial Summary:
- Previous Close: $1.50
- Open: $1.52
- Bid: $1.46 x 200
- Ask: $1.49 x 300
- Day's Range: $1.46 – $1.56
- 52 Week Range: $0.90 – $2.10
- Volume: 442,486
- Average Volume: 544,178
- Market Cap: $166.725M
- Beta (5Y Monthly): -0.21
- PE Ratio (TTM): N/A
- EPS (TTM): -$0.32
- Earnings Date: May 09, 2024 – May 13, 2024
- Forward Dividend & Yield: N/A (N/A)
- 1-Year Target Estimate: $3.75
Key Executives:
- Dr. Ramy A. Mahmoud M.D., M.P.H. (CEO & Director)
- Mr. Michael F. Marino Esq. (Chief Legal Officer & Corporate Secretary)
- Mr. Anthony J. Krick (Vice President & Chief Accounting Officer)
- Mr. Jonathan Neely (Vice President of Investor Relations & Business Operations)
- Ms. Karen E. Brophy (Chief Human Resources Officer & VP of Human Resources)
- Mr. Paul Spence (Chief Commercial Officer)
Financial Analysis:
- OptiNose's revenue for the most recent quarter was $70.99 million, with a revenue growth rate of -4.8%.
- The company's gross margin is 87.8%, with an operating margin of -12.6% and a profit margin of -49.9%.
- OptiNose's market capitalization is $166.73 million, with a price-to-sales ratio of 2.35.
- The company has a trailing EPS of -$0.32 and a forward EPS of -$0.09.
- OptiNose's total cash is $73.68 million, with a total debt of $131.75 million.
Stock Performance:
- OptiNose's stock has a 52-week change of -25% and a 52-week high of $2.10.
- The stock's average daily volume over the past 10 days is 1,484,810, with a short ratio of 7.87.
- Insiders hold 8.97% of the company's shares, while institutions hold 77.62%.
Analyst Opinions:
- OptiNose has a consensus recommendation of "Buy" from 4 analysts.
- The target price range is between $3.00 and $5.00, with a mean target price of $3.75.
Note: All financial information is in USD.
